Patents by Inventor John Michael Ketcham

John Michael Ketcham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRas G12D inhibitors
    Patent number: 12747253
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: September 29, 2026
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James Francis Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20260152505
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.
    Type: Application
    Filed: July 21, 2025
    Publication date: June 4, 2026
    Inventors: Hilary Plake Beck, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, John Michael Ketcham, Jay Patrick Powers, Maureen Kay Reilly, Omar Robles-Resendiz, Hunter Paul Shunatona, James Ross Walker, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky, Jeffrey J. Jackson
  • KRas G12D inhibitors
    Patent number: 12630566
    Abstract: The present invention relates to methods of treating cancer with compounds that inhibit KRas G12D. In particular, the present invention relates to methods of treating non-small cell lung cancer, colorectal cancer, and pancreatic cancer by administering a compound of the following formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 23, 2024
    Date of Patent: May 19, 2026
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • SUBSTITUTED PYRIDOPYRIMIDINONES
    Publication number: 20260078120
    Abstract: Disclosed herein are substituted pyridopyrimidinones, methods for their preparation, and use thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: March 19, 2026
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: JOHN MICHAEL KETCHAM, CHRISTOPHER RONALD SMITH, MATTHEW ARNOLD MARX, JOHN DAVID LAWSON, STEPHEN HARWOOD, AARON CRAIG BURNS, KERSTI CADDELL-HAATVEIT, KELLY ELAINE PEARSON, ATHENEA NOELANI GARDEN ALOIAU, JON KUEHLER, BRIANA BOBEK, ASHLEE HOPE WATKINS, BENJAMIN DONALD JONES, ANTHONY DAVID IVETAC, XIAOLUN WANG
  • SALTS OF SOS1 INHIBITORS
    Publication number: 20250382290
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 18, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: MATTHEW ARNOLD MARX, JOHN MICHAEL KETCHAM, CHRISTOPHER RONALD SMITH, JOHN DAVID LAWSON, AARON CRAIG BURNS, XIAOLUN WANG, SVITLANA KULYK, ANTHONY IVETAC
  • Naphthyridine derivatives as PRC2 inhibitors
    Patent number: 12421228
    Abstract: Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: September 23, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: John Michael Ketcham, Aaron Craig Burns, Matthew Arnold Marx
  • SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS
    Publication number: 20250282787
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: May 22, 2025
    Publication date: September 11, 2025
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • SOS1 INHIBITORS
    Publication number: 20250270220
    Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 7, 2025
    Publication date: August 28, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 12371435
    Abstract: The present invention relates to a process for the preparation of a compound of Formula (G), comprising reacting a compound of Formula (H) with a compound of Formula (D) in the presence of a palladium catalyst to afford the compound of Formula (G).
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: July 29, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER
    Publication number: 20250179082
    Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.
    Type: Application
    Filed: February 5, 2025
    Publication date: June 5, 2025
    Inventors: Matthew Arnold MARX, John Michael KETCHAM, Aaron Craig BURNS
  • Combination therapies
    Patent number: 12280055
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRas G12C inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: April 22, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Jacob Haling, John Michael Ketcham, Shilpi Khare
  • Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
    Patent number: 12252493
    Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 18, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns
  • SOS1 INHIBITORS
    Publication number: 20250059182
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 21, 2022
    Publication date: February 20, 2025
    Inventors: John Michael Ketcham, Christopher Ronald Smith, Matthew Arnold Marx, Xiaolun Wang, Aaron Craig Burns, Svitlana Kulyk, Anthony Ivetac, John David Lawson
  • CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20250059167
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Application
    Filed: August 19, 2024
    Publication date: February 20, 2025
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • COMBINATION THERAPIES
    Publication number: 20250032497
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRas G12C inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.
    Type: Application
    Filed: October 1, 2024
    Publication date: January 30, 2025
    Inventors: Jacob Haling, John Michael Ketcham, Shilpi Khare
  • Substituted Quinoxalines
    Publication number: 20240391882
    Abstract: Disclosed herein are substituted quinoxalines, methods for their preparation, and use thereof.
    Type: Application
    Filed: May 8, 2024
    Publication date: November 28, 2024
    Inventors: Matthew Arnold Marx, Christopher Ronald Smith, John Michael Ketcham, Stephen Harwood, Aaron Craig Burns, John David Lawson, Kersti Caddell-Haatveit
  • Chemokine receptor modulators and uses thereof
    Patent number: 12098139
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: September 24, 2024
    Assignee: RAPT Therapeutics, Inc.
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • KRAS G12D INHIBITORS
    Publication number: 20240309020
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 23, 2024
    Publication date: September 19, 2024
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240208912
    Abstract: Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 27, 2024
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240199620
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.
    Type: Application
    Filed: November 13, 2023
    Publication date: June 20, 2024
    Inventors: Hilary Plake Beck, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, John Michael Ketcham, Jay Patrick Powers, Maureen Kay Reilly, Omar Robles-Resendiz, Hunter Paul Shunatona, James Ross Walker, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky, Jeffrey J. Jackson